Peter A van Dam
Overview
Explore the profile of Peter A van Dam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Jaeghere E, Tuyaerts S, Van Nuffel A, Belmans A, Bogaerts K, Baiden-Amissah R, et al.
Cancer Immunol Immunother
. 2022 Aug;
72(2):475-491.
PMID: 35960332
A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients received an immunomodulatory five-drug cocktail (IDC) consisting of low-dose cyclophosphamide, aspirin, lansoprazole, vitamin...
12.
Dewulf J, Hrynchak I, Geudens S, Pintelon I, Vangestel C, Sereno J, et al.
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631525
Purpose: RANKL expression in the tumor microenvironment has been identified as a biomarker of immune suppression, negating the effect of some cancer immunotherapies. Previously we had developed a radiotracer based...
13.
Debie Y, Vandamme T, Goossens M, van Dam P, Peeters M
Eur J Cancer
. 2022 Jan;
163:177-179.
PMID: 35077960
No abstract available.
14.
De Winter F, Hotterbeekx A, Huizing M, Konnova A, Fransen E, Jongers B, et al.
Cancers (Basel)
. 2021 Nov;
13(22).
PMID: 34830872
Cytokines, chemokines, and (angiogenic) growth factors (CCGs) have been shown to play an intricate role in the progression of both solid and haematological malignancies. Recent studies have shown that SARS-CoV-2...
15.
Van Berckelaer C, Vermeiren I, Vercauteren L, Rypens C, Oner G, Trinh X, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572883
Introduction: Inflammatory breast cancer (IBC) is a rare but aggressive form of breast cancer (BC) in which the (prognostic) role of stromal tumour-infiltrating lymphocytes (sTIL) and the peripheral circulating immune...
16.
Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato D, Onesti C, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503231
Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice,...
17.
Bellens A, Roelant E, Sabbe B, Peeters M, van Dam P
Support Care Cancer
. 2021 Aug;
30(1):21-31.
PMID: 34347183
Introduction: Currently cancer-related cognitive impairment (CRCI) is mainly assessed by means of questionnaires, which is very laborious for the patients and the supervising physician. We evaluated a new online cognitive...
18.
Dewulf J, Vangestel C, Verhoeven Y, De Waele J, Zwaenepoel K, van Dam P, et al.
Cancers (Basel)
. 2021 May;
13(9).
PMID: 33946410
Purpose: The involvement of RANK/RANKL signaling in the tumor microenvironment (TME) in driving response or resistance to immunotherapy has only very recently been recognized. Current quantification methods of RANKL expression...
19.
Verhoeven Y, Quatannens D, Trinh X, Wouters A, Smits E, Lardon F, et al.
Int J Mol Sci
. 2021 Mar;
22(4).
PMID: 33670397
Even though cervical cancer is partly preventable, it still poses a great public health problem throughout the world. Current therapies have vastly improved the clinical outcomes of cervical cancer patients,...
20.
van Dam P, Verhoeven Y, Trinh X
Adv Exp Med Biol
. 2020 Oct;
1277:53-62.
PMID: 33119864
RANK ligand (RANKL) is a member of the tumor necrosis factor alpha superfamily of cytokines. It is the only known ligand binding to a membrane receptor named receptor activator of...